EAM
APLS

Eagle Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Eagle Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-802,253
Closed -$29.1M – 529
2024
Q2 		$29.1M Sell
802,253
-43,280
-5% -$1.96M 0.16% 145
2024
Q1 		$50.5M Buy
845,533
+399,533
+90% +$25.5M 0.26% 132
2023
Q4 		$26.7M Sell
446,000
-3,970
-0.9% -$201K 0.14% 159
2023
Q3 		$17.1M Sell
449,970
-962
-0.2% -$42.3K 0.1% 193
2023
Q2 		$41.1M Buy
450,932
+221,550
+97% +$19.1M 0.23% 133
2023
Q1 		$15.1M Buy
229,382
+93,268
+69% +$5.38M 0.09% 194
2022
Q4 		$6.84M Sell
136,114
-5,103
-4% -$271K 0.04% 289
2022
Q3 		$9.64M Buy
+141,217
New +$8.36M 0.06% 244

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Eagle Asset Management's APLS Position: Q3 2024 in Review

Eagle Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 802,253 shares — an estimated $29.1M sold.

Eagle Asset Management first reported a position in APLS in Q3 2022 and held it in 8 quarters. The position peaked at $50.5M in Q1 2024. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • Eagle Asset Management reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Eagle Asset Management sold 802,253 Apellis Pharmaceuticals shares in Q3 2024, an estimated $29.1M.
  • Eagle Asset Management first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 8 quarters.
  • Eagle Asset Management's Apellis Pharmaceuticals position peaked at $50.5M in Q1 2024.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.